This smallcap pharma company hit record high in a falling market

So far this year, the Themis Medicare stock has surged 33 percent, as against a 10 percent gain in the S&P BSE Sensex,

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Themis Medicare jumped 5 percent to hit a fresh lifetime high of Rs 1,794 per share in Thursday’s intra-day trade after the pharmaceutical company fixed October 10, 2023, as a record date for the purpose of stock split or subdivision of equity shares. In comparison, the S&P BSE Sensex was down 493 points or 0.7 percent to 66,307 levels, as of 10:30 am.

So far this year, the stock of this smallcap pharma company has surged 33 percent, as against a 10 percent gain in the S&P BSE Sensex. The total market capitalisation or m-cap of the company stood at Rs 1,628 crore.

“A record date of October 10 was fixed to determine eligibility of shareholders for sub-division or split of every one fully paid-up equity share having face value of Rs 10 each into 10 fully paid-up equity shares having face value of Re 1 each, as approved by the shareholders in the 53rd Annual General Meeting,” the company said in an exchange filing on September 20.

Follow live blog for constant market updates

That apart, the management also notified that they have incorporated their wholly-owned subsidiary in the name of ‘Rx Themis Private Limited.’

Themis Medicare is a research-based pharmaceutical company specialising in the manufacture of a wide range of products for application areas like pain management, critical care, and anti-infectives.

With a portfolio of over 30 products, the company is present in 17 states catering to 40,000 chemists and 2,000 distributors.

Earlier, credit ratings agency CARE Ratings had reduced long-term bank facilities of Themis Medicare to Rs 62.64 crore from Rs 63.25 crore, but assigned a ‘stable’ review.

In the April-June quarter of 2023-24 (Q1FY24), the company’s revenue from operations rose 2.3 percent to Rs 96 crore from Rs 94 crore, in the year-ago period. Profit after tax (PAT), too, gained 2 percent to Rs 18 crore in Q1FY24.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.